Status:
COMPLETED
Study Investigating the Safety and Tolerability of Multiple Doses of PF-02545920 in Subjects With Schizophrenia
Lead Sponsor:
Pfizer
Conditions:
Schizophrenia
Schizo-affective Disorder
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
To evaluate the safety and tolerability of multiple doses of PF-02545920 subjects with schizophrenia or schizo-affective disorder who are currently clinically stable and to evaluate the serum and urin...
Eligibility Criteria
Inclusion
- Subjects with DSM-IV diagnosis of schizophrenia or schizo-affective disorder for whom antipsychotic monotherapy is indicated.
- Subjects must be free from an acute exacerbation of psychosis for at least 3 months prior to screening.
- Current Clinical Global Impression (CGI) of Severity of Illness score ≤ 3.
Exclusion
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- Evidence or history of a primary DSM-IV axis I diagnosis other than schizophrenia or schizoaffective disorder.
- Any condition possibly affecting drug absorption (e.g., gastrectomy).
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
End Date :
May 1 2007
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00463372
Start Date
October 1 2006
End Date
May 1 2007
Last Update
September 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
George, South Africa